Linda Tharby

Linda Tharby

Chief Executive Officer and President, Director since 2022

Ms. Tharby has served as the Company’s Chief Executive Officer since April 2021. Ms. Tharby has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize products and service innovations, while delivering solutions to patients in the home setting. Prior to joining the Company, Ms. Tharby spent the last 24 years working in various roles of increased responsibility at Becton Dickinson (“BD”). Ms. Tharby was a member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology company. Ms. Tharby’s most recent role at BD was Chief Customer Experience Officer from July 2018 through December 2020. In her prior role, as BD’s Chief Human Resources Officer, from October 2016 through July 2018, she led the company through its $24 billion acquisition and integration of C.R. Bard in 2017. She also held numerous global business leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre-Analytical Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby has an Honors Bachelor of Business Administration from Wilfrid Laurier University in Waterloo, Ontario Canada.

Tom Adams

Tom Adams

Chief Financial Officer

Tom joins KORU with medical device industry experience, coming from Integra Life Sciences, where he spent the last 10 years, with his most recent role there as Senior Director of Finance (FP&A).  Previous roles included Group Controller/Head of FP&A and Director of Finance (FP&A). Career highlights include establishing the Finance function for a newly created manufacturing division at Integra, which involved creating processes, setting up systems for reporting, management presentations and hiring a strong team. Tom recently led the financial analysis and negotiation to move Integra’s headquarters to Princeton, NJ, which this deal was recently awarded NJ’s 2019 office real estate deal of the year! He earned his Bachelor of Science in Business Administration-Accounting & Finance from Ohio State University. Tom brings extensive expertise and experience in building forecasts, budgets, modeling, and cost accounting that will support decision making and actions to help drive KORU’s growth.

Brian Case

Brian Case

Chief Technology Officer

Brian joins the KORU Medical Systems team with over 20 years of research and development experience. Most recently, he spent over 16 years at Fresenius Kabi, a global healthcare company specializing in lifesaving medicines and technologies, as Vice President, Research and Development. Mr. Case provided business and technical leadership for the Transfusion and Cell Technologies division to drive long-term product vitality and competitive advantage of the business and promote entry into new business areas. Prior to Fresenius Kabi, Mr. Case spent six years at Cook Medical, a medical device company, as R&D Program Manager, Advanced Research. While there, he managed a cross-functional team that developed and assessed new technologies to create a product portfolio to service the peripheral disease market. Mr. Case received his Master of Science in Engineering Management from the Rose-Hulman Institute of Technology, and his Bachelor of Science in Engineering Mechanics, from the University of Illinois. In addition, Mr. Case is an inventor on over 100 patents, a Licensed Professional Mechanical Engineer, and a Certified Project Management Professional.
Ken Miller

Ken Miller

Chief Commercial Officer

Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability.  Ken joins KORU Medical with impressive medical device and pharmaceutical industry experience, most recently from NASCO Healthcare where he spent five years as President & CEO. At NASCO, he transformed sales & marketing, and led the consolidation of NASCO’s manufacturing footprint which delivered year-over-year double digit revenue and EBITDA growth.   Prior to NASCO, Ken spent 7 years at Becton Dickinson (NYSE: BDX) with his last role as the Worldwide President Diabetes Care where he led the transition from a product focus to a full-service diabetes management solution provider. Ken also held leadership roles in marketing, sales, and business development with Novo Nordisk, Adams Respiratory Therapeutics, and Roche Laboratories.  Ken earned his Bachelor of Arts in Business Management from State University of New York at Albany and his Master of Business Administration from The University of Chicago, Booth School of Business.

Chris Pazdan

Chris Pazdan

Senior Vice President, Operations

Chris joins the KORU team from Hillrom where he worked as the Vice President of Quality Assurance. In that role he was responsible for all quality functions for Hillrom’s largest manufacturing division. Prior to that role, Chris was the Vice President of QA/RA where he was responsible for enterprise-wide Design Assurance, Supplier Quality Assurance, Project Management Office, and Software. Chris’ proudest professional accomplishments include working with, leading, and helping build great teams. In addition to these efforts, he enjoys making a difference in the healthcare space and improving outcomes for patients and customers.

Chris received his bachelor’s degree in general engineering from the University of Illinois at Urbana-Champaign. He is a ASQ Certified Six Sigma Black Belt, ASQ Certified Quality Engineer and an ASQ Certified Quality Auditor.

Rob Cannon

Rob Cannon

Vice President of Sales

Rob brings 30+ years of experience in sales across the healthcare industry with direct experience in home care, specialty pharmacy and with Plasma/Biologics.  Most recently, he served as the Vice President of Strategic Accounts for McKesson Alternate Pharmacy Solutions, where he led the strategy, planning, and implementation of effective sales and marketing strategies focused on the specialty pharma channel. Prior to that role, Rob was the Vice President of Sales for McKesson Plasma and Biologics, where he established and managed a sales team, and as the Senior Director for McKesson Alternate Site Pharmacy, where he spearheaded the development and execution of strategic programs enhancing pharmacy partnerships while also driving value and efficiency. Rob received his Bachelor of Science degree in chemistry from Fordham University. 

Brent Rutland

Brent Rutland

Vice President of Global Medical Affairs

Brent joins KORU with more than 25 years of experience in Medical Affairs.  Prior to joining KORU, Brent was with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his tenure he has helped launch 7 vaccines, 4 drugs and 1 device.  Most notably, Brent aided Baxter in the launch of Hylenex for Pediatric SQ rehydration where he also helped build the Medical Affairs department.  Brent has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla.  Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston and his Master of Public Health from the University of North Carolina in Epidemiology.  

Brian Hertzog

Brian Hertzog

Vice President of Business Development

Brian Hertzog comes to Koru with over 15 years of experience in the drug delivery and medical device space. Most recently he was a business development executive at Nemera, a diversified drug delivery company with inhalation, ENT, ophthalmic, dermal, and parenteral devices (both autoinjectors and on-body wearables). He has deep experience in infusion devices and pharmaceutical packaging, also having held business development roles at Unilife, Schott, and Datwyler.